Direxion Daily S&P Biotech Bull 3X Shares (LABU)
| Assets | $930.41M |
| Expense Ratio | 0.96% |
| PE Ratio | n/a |
| Shares Out | 9.67M |
| Dividend (ttm) | $0.58 |
| Dividend Yield | 0.68% |
| Ex-Dividend Date | Mar 19, 2024 |
| Payout Ratio | n/a |
| 1-Year Return | -27.93% |
| Volume | 2,739,473 |
| Open | 86.89 |
| Previous Close | 88.04 |
| Day's Range | 81.12 - 90.97 |
| 52-Week Low | 48.40 |
| 52-Week High | 176.99 |
| Beta | 3.21 |
| Holdings | 148 |
| Inception Date | May 28, 2015 |
About LABU
Fund Home PageThe Direxion Daily S&P Biotech Bull 3X Shares (LABU) is an exchange-traded fund that is based on the S&P Biotechnology Select Industry index. The fund provides daily 3 times exposure to the S&P Biotechnology Select Industry Index. LABU was launched on May 28, 2015 and is issued by Direxion.
Top 10 Holdings
258.40% of assets| Name | Symbol | Weight |
|---|---|---|
| S&P BIOTECHNOLOGY SELECT INDUSTRY INDEX SWAP | n/a | 41.17% |
| S&P BIOTECHNOLOGY SELECT INDUSTRY INDEX SWAP | n/a | 40.76% |
| S&P BIOTECHNOLOGY SELECT INDUSTRY INDEX SWAP | n/a | 35.56% |
| S&P BIOTECHNOLOGY SELECT INDUSTRY INDEX SWAP | n/a | 33.89% |
| S&P BIOTECHNOLOGY SELECT INDUSTRY INDEX SWAP | n/a | 26.10% |
| S&P BIOTECHNOLOGY SELECT INDUSTRY INDEX SWAP | n/a | 24.17% |
| S&P BIOTECHNOLOGY SELECT INDUSTRY INDEX SWAP | n/a | 22.40% |
| DREYFUS GOVT CASH MAN INS | n/a | 18.31% |
| GOLDMAN FINL SQ TRSRY INST 506 | n/a | 12.60% |
| GOLDMAN SACHS FIN GOV 465 INSTITUT | n/a | 3.44% |
Dividends
| Ex-Dividend | Amount | Pay Date |
|---|---|---|
| Mar 19, 2024 | $0.16064 | Mar 26, 2024 |
| Dec 21, 2023 | $0.20968 | Dec 29, 2023 |
| Sep 19, 2023 | $0.0404 | Sep 26, 2023 |
| Jun 21, 2023 | $0.1736 | Jun 28, 2023 |
| Dec 23, 2019 | $0.1062 | Dec 31, 2019 |
| Sep 24, 2019 | $0.2168 | Oct 1, 2019 |
News
Taking On Volatility With Geared ETFs
Direxion's Dave Mazza is seeing many traders using inverse and leveraged ETFs in the recent market movement.
A Biotech ETF For Aggressive, Risk-Tolerant Investors
The biotechnology sector has been on fire thanks to news from Biogen Inc. (NASDAQ: BIIB). The FDA approved its controverisal drug that can treat Alzheimer's Disease.
Heating Up: Three Leveraged ETFs For Summer Earnings
As the broad market knocks on the door of all-time highs in the midst of a still-raging public health crisis, traders have had to simultaneously ride the bullish wave (in most sectors) while also mode...
With Biotech Scorching, Traders Show LABU Love
The coronavirus pandemic is fueling gains for biotechnology exchange traded funds this year and the leverage members of this group are participating in the fun.
3 Leveraged Healthcare ETFs Soaring This Month
The new coronavirus from China has claimed more than 800 lives and there are now more than 37,000 documented cases of the respiratory illness worldwide, making it more deadly than the 2003 SARS epidem...
Where to Buy Booming Biotech ETFs
Discover why biotech stocks are surging despite large fund outflows. Monitor these three industry ETFs for "buy the dip" opportunities.
Jablonski: Biotech presents a good buying opportunity
Sylvia Jablonski of Direxion discusses why biotech stocks and ETFs are attractive right now, due to their cheapness relative to the rest of the market.
These Are The Leveraged ETFs At Play When Trade War Worries Strike
The U.S.-China trade war is more than 18 months old. And in that time the conflict has taken a toll on stocks across the world and put company executives and market watchers alike on edge.
Biotech stocks fall after Trump promises executive order drug prices
CNBC's Meg Tirrell reports on the dip in biotech stocks after President Donald Trump promised that an executive order on drug prices is coming.
A Beloved Biotech ETF Could Lure Traders Again
With biotechnology stocks and the related exchange-traded funds recently showing some signs of life, it could be just a matter of time before aggressive traders embraced leveraged healthcare ETFs.
It's Time To Consider Leveraged Healthcare ETFs
For traders using leveraged sector exchange-traded funds, one key to successfully using these products in the short-term fashion in which they are intended is to treat leveraged ETFs as event-driven t...
Big Moves In Leveraged Biotech ETFs
Leveraged biotechnology exchange traded funds (ETFs) are known to make big moves, but sometimes those moves are not always about price action.